Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Merus NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Merus NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Merus NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Merus NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Merus NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Merus NV, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Merus Raises USD55.8 Million in Venture Financing 12
Merus Raises USD46.4 Million in First Tranche of Series C Financing 13
Merus Raises US$42 Million In Extended Series B Financing 15
Private Equity 17
Biotechnology Value Fund to Invest USD55.8 million in Merus 17
Partnerships 18
Integral Molecular Enters into Agreement with Merus 18
Merus Enters into Research Agreement with Vall d’Hebron Institute of Oncology 19
Merus Enters into Research Agreement with Institute for Research in Biomedicine 20
Merus Enters into Co-Development Agreement with Institut Gustave Roussy 21
Licensing Agreements 22
Ono Pharma Enters into Licensing Agreement with Merus 22
Simcere Pharma to Enter into Licensing Agreement with Merus 23
Incyte Enters into Licensing Agreement with Merus 24
Ono Pharma Exercises Option for Licensing Agreement with with Merus 26
ProBioGen Enters into Licensing Agreement with Merus 27
ProBioGen Enters Into Licensing Agreement With Merus For GlymaxX ADCC Technology 28
Equity Offering 29
Merus Raises USD80 Million in Private Placement 29
Merus Announces Partial Exercise of Underwriter’s Option for IPO for USD61.39 Million 30
Merus NV – Key Competitors 32
Merus NV – Key Employees 33
Merus NV – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Financial Announcements 35
Aug 10, 2018: Merus announces financial results for the second quarter 2018 & mid-year operating results 35
Jul 26, 2018: Merus Announces Recent Corporate Developments and Financial Results for the First Quarter 2018 37
Apr 26, 2018: Merus Announces Recent Corporate Developments and Financial Results for the Fourth Quarter and Full Year 2017 39
Nov 30, 2017: Merus Announces Third Quarter 2017 Financial Results and Clinical Highlights 42
Sep 19, 2017: Merus Announces Second Quarter 2017 Financial Results and Highlights Recent Progress 44
Jul 11, 2017: Merus Announces First Quarter 2017 Financial Results And Mid-Year Operating Results 45
Apr 28, 2017: Merus Announces Fourth Quarter and Full Year 2016 Financial Results and Corporate Developments 47
Corporate Communications 49
Sep 27, 2018: Merus strengthens team with key appointments 49
Aug 22, 2018: Merus announces formation of a scientific advisory board 50
Legal and Regulatory 51
Dec 27, 2017: Merus Announces the U.S. Court of Appeals for the Federal Circuit Denies Regeneron’s Petition to Rehear the Panel’s Decision Affirming Merus’ Inequitable Conduct Claim Against Regeneron 51
Jul 28, 2017: U.S. Court of Appeals for the Federal Circuit Affirms Merus’ Inequitable Conduct Claim Against Regeneron 52
Product News 53
04/20/2017: Merus Announces Data from a Phase 1/2 Study of MCLA-128 to be Presented at the 2017 American Society of Clinical Oncology Annual Meeting 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54
Merus NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Merus NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Merus NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Merus NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Merus NV, Deals By Therapy Area, 2012 to YTD 2018 9
Merus NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Merus Raises USD55.8 Million in Venture Financing 12
Merus Raises USD46.4 Million in First Tranche of Series C Financing 13
Merus Raises US$42 Million In Extended Series B Financing 15
Biotechnology Value Fund to Invest USD55.8 million in Merus 17
Integral Molecular Enters into Agreement with Merus 18
Merus Enters into Research Agreement with Vall d’Hebron Institute of Oncology 19
Merus Enters into Research Agreement with Institute for Research in Biomedicine 20
Merus Enters into Co-Development Agreement with Institut Gustave Roussy 21
Ono Pharma Enters into Licensing Agreement with Merus 22
Simcere Pharma to Enter into Licensing Agreement with Merus 23
Incyte Enters into Licensing Agreement with Merus 24
Ono Pharma Exercises Option for Licensing Agreement with with Merus 26
ProBioGen Enters into Licensing Agreement with Merus 27
ProBioGen Enters Into Licensing Agreement With Merus For GlymaxX ADCC Technology 28
Merus Raises USD80 Million in Private Placement 29
Merus Announces Partial Exercise of Underwriter’s Option for IPO for USD61.39 Million 30
Merus NV, Key Competitors 32
Merus NV, Key Employees 33
Merus NV, Subsidiaries 34
List of Figures
Merus NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Merus NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Merus NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Merus NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Merus NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Merus NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Merus NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Merus NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9